TD Cowen downgrades Kronos Bio (KRON) to a Hold
Kronos Bio (KRON – Research Report) received a Hold rating and price target from TD Cowen analyst Tyler Van Buren yesterday. The ...
Business Insider17h
Positive Outlook for Oruka Therapeutics: Promising Developments with ORKA-001
Tyler Van Buren has given his Buy rating due to a combination of factors surrounding Oruka Therapeutics’ promising developments with their lead antibody, ORKA-001. The extended half-life of ORKA-001, ...
Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Successful go-public transaction and over $475 million raised this year provides cash runway through multiple clinical ...
Oruka Therapeutics (ORKA) versus The Competition Critical Contrast
Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) is one of 39 publicly-traded companies in the “Diagnostic substances” industry, but how does it contrast to its competitors? We will compare Oruka ...
Contrasting Oruka Therapeutics (ORKA) & The Competition
Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) is one of 39 public companies in the “Diagnostic substances” industry, but how does it weigh in compared to its peers? We will compare Oruka ...